Human CNDP1 Protein (His Tag)

CN1,CPGL2,HsT2308

• 100ug (NPP3747) Please inquiry

Catalog Number	P10077-H08H
Organism Species	Human
Host	Human Cells
Synonyms	CN1,CPGL2,HsT2308
Molecular Weight	The recombinant human CNDP1 consists of 492 amino acids and has a calculated molecular mass of 55.3 kDa. As a result of glycosylation, the protein migrates as an approximately 60-65 kDa band in SDS-PAGE under reducing conditions.
predicted N	Ser 27
SDS-PAGE
Purity	> 90 % as determined by SDS-PAGE and SEC-HPLC Analysis.
Protein Construction	A DNA sequence encoding the mature form of human CNDP1 (NP_116038.4) (Ser27-His507) was fused with a polyhistidine tag at the C-terminus.
Bio-activity	Measured by its ability to cleave carnosine (β­Ala­L­His) in a two­step assay. The specific activity is > 250 pmoles/min/μg.
Research Area	Cancer |Invasion microenvironment |Adhesion molecule |Extracelluar matrix |Extracellualr matrix proteases & regulators |Matrix metalloproteinase (MMP) |
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	CNDP1, also known as carnosine dipeptidase 1, glutamate carboxypeptidase-like protein 2 (CPGL-2) or carnosinase 1 (CN1), is a member of the M20 metalloprotease family. The CNDP1 gene contains trinucleotide (CTG) repeat length polymorphism in the coding region, which has been demonstrated to be associated with susceptibility to developing diabetic nephropathy, for carnosine protection against the adverse effects of high glucose levels on renal cells. In humans, CNDP1 is secreted from the liver into the serum. In other mammals, including rodents, CNDP1 is expressed exclusively within the kidney and lacks a signal peptide. CNDP1 protein is a secreted homodimeric dipeptidase that specifically hydrolyzes L-carnosine (β-alanyl-L-histidine), and is identified as human carnosinase expressed in the brain. CNDP1 has been associated with diabetic nephropathy in Europeans and European Americans, but not African-Americans. It was identified and confirmed as a risk factor, were cross-sectional and mostly in patients with type 2 diabetes. The polymorphisms of CNDP1 can be excluded as a risk factor for nephropathy in type 1 diabetes. In addition, CNDP1 is also suggested to be implicated in the actions of neuroprotection and neurotransmiting.
Reference	Teufel M, et al. (2003) Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 278(8):6521-31. Janssen B, et al. (2005) Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 54(8):2320-7. Riedl E, et al. (2007) A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes 56(9):2410-3. Freedman BI, et al. (2007) A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 22(4):1131-5. Wanic K, et al. (2008) Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. Diabetes 57(9):2547-51. McDonough CW, et al. (2009) The influence of carnosinase gene polymorphisms on diabetic nephropathy risk in African-Americans. Hum Genet. 126(2):265-75.